Latest Zandelisib TIDAL Data "Impressive, Supports Outlook" - Brookline Capital Markets Reiterates MEI Pharma (MEIP) at Buy with $15 Price Target
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $15.00 price target on MEI Pharma (NASDAQ: MEIP) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
